Abbott Laboratories is set to announce its second-quarter 2025 results on July 17. The projected revenue stands at $11.07 billion, marking a 6.7% increase from the previous year. Expected earnings per share (EPS) is projected at $1.25, reflecting a 9.6% year-over-year growth.
The Medical Devices segment is anticipated to have contributed to this growth, driven by the adoption of continuous glucose monitors and cardiac devices. Recently, the approval of the Tendyne transcatheter mitral valve replacement system has been a noteworthy development.
The company’s Established Pharmaceuticals Division is forecasted to achieve a 6.1% revenue increase. This is attributed to robust performance in regions and therapeutic areas like gastroenterology and biosimilars.
In the Nutrition sector, sales of adult nutrition brand Ensure are expected to bolster second-quarter growth, while robust sales in infant and toddler brands are anticipated. The segment is projected to see a 4.3% rise in second-quarter revenues.
With an Earnings ESP of +0.96% and a Zacks Rank #2, Abbott is well-positioned to exceed earnings estimates. Comparable potential in beat estimates is seen in CVS Health, Cencora, and Cardinal Health, all anticipated to release their earnings soon.
Abbott’s second-quarter release on 17 July presents a rather straightforward picture: revenue projections of $11.07 billion represent an increase just shy of seven percent compared to the same period last year, while earnings per share are pencilled in at $1.25—a near ten percent lift. This is not a staggering jump, but it does suggest that business is developing steadily across key verticals.
Once we look into the segments, the Medical Devices division appears to be at the forefront of this push. The wider adoption of continuous glucose monitors and an uptick in usage of cardiac devices lend momentum here. Additionally, the recent regulatory success with their mitral valve replacement device adds another driver for long-term product viability in cardiac care. While approvals such as this don’t contribute right away to the bottom line in a measurable way, they often stimulate revisions to growth expectations across subsequent quarters.
Abbott’s pharmaceutical arm, referred to internally as the Established Pharmaceuticals Division, is tracked as showing around a six percent income rise, supported largely by sales across digestive and biosimilar categories with increased uptake in international markets. That said, biosimilars remain sensitive to regional pricing differences and competition, so any emerging patterns from conference commentary or updated guidance could create disparities in short-term sentiment.
On the nutrition side, the key theme is reliable consumer demand. Brands marketed to adults are expected to perform well—Ensure being a key contributor. However, a considerable portion of the optimism actually hinges on their pediatric branch. Infant and toddler nutrition are often more consistent and regionally defensible businesses, leading to the expected four percent revenue rise in this category. Whether this carries through into the next quarter depends largely on inventory replenishments and demographic tailwinds, aspects that are tracked closely but that may not be visible until Q3 data.
The current earnings surprise prediction (a positive ESP of 0.96%) combined with the model’s assessment rank implies a decent probability that the published figures will come in above consensus estimates. But estimates themselves have firmed in recent weeks, reducing the buffer. One could suggest that the magnitude of any upside may be more muted than in prior quarters unless a distinction emerges either in operational margins or geographical contributions.
It’s informative to note which names are modelled alongside Abbott in terms of beat potential. CVS and Cencora, once known primarily for distribution, are increasingly relevant for comparative metrics in pharma-related earnings plays, especially as they broaden service offerings. Likewise, Cardinal could surprise but its sensitivity to generics pricing and product mix shifts might bring more volatility post-earnings. While the sector does often trade in clusters, tracking the respective reports with a short lag can offer more precise pair trade setups depending on where deviations are found.
For us, this presents a context-powered environment—one that benefits from watching not only financial beats but operational run-rates within each subdivision. Particularly, moves in margins across devices and nutrition could offer early clues about pricing influence or cost controls that trickle down into the next half of the year. If device sales come in above expectation but operating income doesn’t reflect this, further inspection into supply chain costs or R&D spillovers would be warranted.
As July advances, expectations are now better-defined. Momentum in the devices business provides a lead indicator, but any model recalibration should be responsive to unit-level demand signals, not just dollar sales. Assuming no forward guidance revision, the variation from consensus EPS will carry more weight on positioning adjustments in the days following the report.
